CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and Tolerability of OROS Hydromorphone in Strong Opioid-Naïve Patients:An Open Label, Prospective Study
Jun-Eul Hwang, Dae-Eun Kim, Ha-Na Kim, Ju-young Yoon, Woo-Kyun Bae, Hyun-Jeong Shim, Sang-Hee Cho, Ik-Joo Chung
Korean J Med. 2011;80(3):317-322.   Published online 2011 March 1

Excel Download

A Prospective Multicentre Study to Evaluate the Efficacy and Tolerability of Osmotic Release Oral System (Oros®) Hydromorphone in Opioid-Naive Cancer Patients: Results of the Korean South West Oncology Group Study
Pain Research and Management. 2015;20(6):293-299   Crossref logo
Link1 Link2

Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis
Clinical Therapeutics. 2007;29(5):874-888   Crossref logo
Link1 Link2

Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended-Release (OROS®hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain
Pain Practice. 2012;13(1):30-40   Crossref logo

Open-label extension study on the long-term efficacy, safety, and impact on quality of life of OROS® hydromorphone extended release in patients with chronic low back pain
The Journal of Pain. 2009;10(4):S49   Crossref logo
Link1 Link2

Open-Label Study on the Long-Term Efficacy, Safety, and Impact on Quality of Life of OROS Hydromorphone ER in Patients with Chronic Low Back Pain
Pain Medicine. 2010;11(10):1477-1488   Crossref logo

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain
BMC Palliative Care. 2009;8(1):   Crossref logo
Link1 Link2 Link3

Efficacy and tolerability of OROS hydromorphone extended release in patients with moderate to severe osteoarthritis pain: a phase 3, flexible-dose, randomized, double-blind, placebo-controlled study
The Journal of Pain. 2012;13(4):S84   Crossref logo
Link1 Link2

An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis
Clinical Therapeutics. 1995;17(4):701-707   Crossref logo
Link1 Link2

Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study
Clinical Therapeutics. 2006;28(5):745-754   Crossref logo
Link1 Link2

Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
Journal of Pain Research. 2013;319   Crossref logo

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Med has participated in CrossRef Text and Data Mining service since September 11, 2015.